JPRN-UMIN000030082已完成未知
Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma. - Long term follow-up study of gefitinib vs erlotinib for lung adenocarcinoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 561
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
3 期
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
已完成
不适用
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)on-small cell lung cancerJPRN-UMIN000006340orth-East Japan Study Group345
未知
不适用
A phase II study of gefitinib in PS3 (4) advanced adenocarcinoma of the lungPS 3 patients (or PS 4 patients because of bone or brain metastasis) with advanced adenocarcinoma of the lung.JPRN-C000000187Department of Medical Oncology, Kinki University School of Medicine30
已完成
2 期
Phase II study of gefitinib in untreated advanced non-small cell lung cancer with EGF receptor mutationsnon-small cell lung cancerJPRN-C000000184Hokkaido Lung Cancer Clinical Study Group16
已完成
2 期
Phase II study of gefitinib therapy inserted by chemotherapy as first line treatment for advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutatioon-small-cell lung cancerJPRN-UMIN000001738Thoracic Medical Oncology, National Cancer Center Hospital33